Dutasteride
FDA-approved product (capsule, oral), marketed as Avodart, Dutasteride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Benign prostatic hyperplasia
- Prostate adenocarcinoma
- Prostate carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Testosterone-5-alpha reductase inhibitors
- FDA pharmacologic class
- 5-alpha Reductase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dutasteride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Enalapril MaleateExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BendroflumethiazideExisting use: Cardiovascular disease, Hypertension68.8% AI-predicted activityagainst M. tuberculosis9 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more68.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorothiazideExisting use: Cardiovascular disease, Chronic kidney disease, Congestive heart failure and 6 more68.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more68.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more68.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RiociguatExisting use: Hypertension, Idiopathic and/or familial pulmonary arterial hypertension, Pulmonary arterial hypertension and 1 more68.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TrichlormethiazideExisting use: Cardiovascular disease67.9% AI-predicted activityagainst M. tuberculosis1 registered study
- Promazine HydrochlorideExisting use: Psychosis67.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more67.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydroflumethiazideExisting use: Cardiovascular disease67.7% AI-predicted activityagainst M. tuberculosis1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
Testosterone and Its Metabolites in GID
NCT00146146 · start 2005-05
Registered record
- Registry ID
- NCT00146146
- Conditions
- Transsexualism
- Interventions
- testosterone undecanoate alone; testosterone undecanoate plus letrozole; testosterone undecanoate plus dutasteride
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-05
- Completion
- 2008-01
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTranssexualismInterventiontestosterone undecanoate alone; testosterone undecanoate plus letrozole; testosterone undecanoate plus dutasteridePhasePhase 3Registry statusCompletedEffects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00375765 · start 2005-04
Registered record
- Registry ID
- NCT00375765
- Conditions
- Benign Prostatic Hyperplasia; Prostate Cancer
- Interventions
- Dutasteride
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-04
- Completion
- 2007-07
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic Hyperplasia; Prostate CancerInterventionDutasteridePhasePhase 4Registry statusCompletedOral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone
NCT00161421 · start 2005-03
Registered record
- Registry ID
- NCT00161421
- Conditions
- Contraception; Hypogonadism
- Interventions
- Oral Testosterone; Leuprolide (Lupron); Dutasteride
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2006-07
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionContraception; HypogonadismInterventionOral Testosterone; Leuprolide (Lupron); DutasteridePhasePhase 2Registry statusCompletedAVODART(Dutasteride) Post-marketing Surveillance(PMS)
NCT01299571 · start 2004-12
Registered record
- Registry ID
- NCT01299571
- Conditions
- Benign Prostatic Hyperplasia; Prostatic Hyperplasia
- Interventions
- Dutasteride
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2004-12
- Completion
- 2010-07
- Enrolment
- 3,977
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic Hyperplasia; Prostatic HyperplasiaInterventionDutasteridePhaseNot recordedRegistry statusCompletedObservational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
NCT00316732 · start 2004-10-25
Registered record
- Registry ID
- NCT00316732
- Conditions
- Prostatic Hyperplasia
- Interventions
- IPSS Questionnaire; EQ-5D Questionnaire
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2004-10-25
- Completion
- 2006-12-19
- Enrolment
- 173
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstatic HyperplasiaInterventionIPSS Questionnaire; EQ-5D QuestionnairePhaseNot recordedRegistry statusCompleted